LOS ANGELES, CA--(Marketwired - Jun 10, 2013) - MMRGlobal, Inc. (
On April 24, 2013, Robert H. Lorsch, MMRGlobal CEO, hosted Luo Jianhui, Unisoft Group/Unis-Tonghe Technology Vice President and Chairman, and jointly announced that the two companies were in the process of finalizing a new design for a recently announced Henan government medical project, which plans on using a Chinese version of the MMR Personal Health Record provisioned through the Joint Venture. The system also includes two-way provider and patient connectivity with any EMR or EHR system as well as an integrated HL7 interface and the ability to populate data directly to the patient including lab test results, medication lists and other discrete data. The two companies are also discussing a separate venture where they would jointly sell to the global Chinese market wherever MMR holds its patents. That version will also be used for the Primary Health Care Institutions Management Information System Construction Project.
The Joint Venture was formally submitted for approval to the Chinese government in 2011 after which Unis-Tonghe MMR International Health Management Service Co., Ltd. received its Articles of Association and licenses in 2012 to operate in China through 2042. The Chinese government has mandated regulations and initiatives for health care including health IT, which include financial incentives that are similar to those in the U.S. and should help drive EMR and PHR revenues to the Joint Venture. The two companies have agreed that the Joint Venture will be headquartered in the Unisplendour Cloud Industrial Park, in the city of Zhengzhou, in Henan Province.
MMR is a leading provider of Personal Health Records, MyEsafeDepositBox storage solutions, and MMRPro document management and imaging systems for health care professionals. The MMR Patent Portfolio includes seven issued U.S. patents -- U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240 -- as well as additional applications and continuation applications including nearly 400 claims. The patents involve inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. MMR also has been granted patents and has other pending applications in countries of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, China, Hong Kong, South Korea, Israel, and European nations. The Company's health IT patent portfolio was the subject of a May 2, 2013 report on Personal Health Records that concluded that the value of the Company's U.S. patents could reach between $800 million to $1.1 billion in revenue (available at http://michaelbass.com/PDF/Patent_Valuation.pdf).
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.
All statements in this press release that are not strictly historical in nature, whether or not such statement relates directly to the Unis-Tonghe MMR Joint Venture, and the Company's future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company's products are not adopted or viewed favorably by the healthcare community in the U.S. and internationally; business prospects, results of operations or financial condition; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product introductions; ability to establish and maintain strategic relationships and partnerships; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission, including disclosures about the Company's relationship with the Michael Bass Group since 2009. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
- Health Care Industry
- Electronic Medical Records
- information technology
- Joint Venture
Public Communications Co.